These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 21871984)

  • 21. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.
    Adem C; Reynolds C; Soderberg CL; Slezak JM; McDonnell SK; Sebo TJ; Schaid DJ; Myers JL; Sellers TA; Hartmann LC; Jenkins RB
    Cancer; 2003 Jan; 97(1):1-11. PubMed ID: 12491499
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Frequency of Contralateral Prophylactic Mastectomy in Breast Cancer Patients with a Negative BRCA1 and BRCA2 Rapid Genetic Test Result.
    Metcalfe KA; Eisen A; Poll A; Candib A; McCready D; Cil T; Wright F; Demsky R; Mancuso T; Sun P; Narod SA
    Ann Surg Oncol; 2021 Sep; 28(9):4967-4973. PubMed ID: 33761021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnostic breast magnetic resonance imaging and contralateral prophylactic mastectomy.
    Sorbero ME; Dick AW; Beckjord EB; Ahrendt G
    Ann Surg Oncol; 2009 Jun; 16(6):1597-605. PubMed ID: 19330381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contralateral risk-reducing mastectomy in BRCA1 and BRCA2 mutation carriers and other high-risk women in the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).
    Kiely BE; Jenkins MA; McKinley JM; Friedlander ML; Weideman P; Milne RL; McLachlan SA; Hopper JL; Phillips KA
    Breast Cancer Res Treat; 2010 Apr; 120(3):715-23. PubMed ID: 19669874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of contralateral prophylactic mastectomy and the impact on breast reconstruction.
    Pinell-White XA; Kolegraff K; Carlson GW
    Ann Plast Surg; 2014; 72(6):S153-7. PubMed ID: 24691345
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Jernström H; Lubinski J; Lynch HT; Ghadirian P; Neuhausen S; Isaacs C; Weber BL; Horsman D; Rosen B; Foulkes WD; Friedman E; Gershoni-Baruch R; Ainsworth P; Daly M; Garber J; Olsson H; Sun P; Narod SA
    J Natl Cancer Inst; 2004 Jul; 96(14):1094-8. PubMed ID: 15265971
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations.
    Schrag D; Kuntz KM; Garber JE; Weeks JC
    N Engl J Med; 1997 May; 336(20):1465-71. PubMed ID: 9148160
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors.
    Graves KD; Peshkin BN; Halbert CH; DeMarco TA; Isaacs C; Schwartz MD
    Breast Cancer Res Treat; 2007 Sep; 104(3):321-9. PubMed ID: 17066320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.
    Metcalfe K; Lynch HT; Ghadirian P; Tung N; Olivotto I; Warner E; Olopade OI; Eisen A; Weber B; McLennan J; Sun P; Foulkes WD; Narod SA
    J Clin Oncol; 2004 Jun; 22(12):2328-35. PubMed ID: 15197194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Less correspondence between expectations before and cosmetic results after risk-reducing mastectomy in women who are mutation carriers: a prospective study.
    Brandberg Y; Arver B; Johansson H; Wickman M; Sandelin K; Liljegren A
    Eur J Surg Oncol; 2012 Jan; 38(1):38-43. PubMed ID: 22032910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer.
    Pierce LJ; Levin AM; Rebbeck TR; Ben-David MA; Friedman E; Solin LJ; Harris EE; Gaffney DK; Haffty BG; Dawson LA; Narod SA; Olivotto IA; Eisen A; Whelan TJ; Olopade OI; Isaacs C; Merajver SD; Wong JS; Garber JE; Weber BL
    J Clin Oncol; 2006 Jun; 24(16):2437-43. PubMed ID: 16636335
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Should the use of contralateral prophylactic mastectomy be increasing as it is?
    Wood WC
    Breast; 2009 Oct; 18 Suppl 3():S93-5. PubMed ID: 19914552
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer.
    Kaas R; Verhoef S; Wesseling J; Rookus MA; Oldenburg HS; Peeters MJ; Rutgers EJ
    Ann Surg; 2010 Mar; 251(3):488-92. PubMed ID: 20134318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature.
    Kirova YM; Savignoni A; Sigal-Zafrani B; de La Rochefordiere A; Salmon RJ; This P; Asselain B; Stoppa-Lyonnet D; Fourquet A
    Breast Cancer Res Treat; 2010 Feb; 120(1):119-26. PubMed ID: 20033769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Local Therapy Decision-Making and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast Cancer.
    Rosenberg SM; Sepucha K; Ruddy KJ; Tamimi RM; Gelber S; Meyer ME; Schapira L; Come SE; Borges VF; Golshan M; Winer EP; Partridge AH
    Ann Surg Oncol; 2015 Nov; 22(12):3809-15. PubMed ID: 25930247
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series.
    Robson M; Svahn T; McCormick B; Borgen P; Hudis CA; Norton L; Offit K
    Cancer; 2005 Jan; 103(1):44-51. PubMed ID: 15558796
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Contralateral prophylactic mastectomy for unilateral breast cancer: an increasing trend at a single institution.
    Jones NB; Wilson J; Kotur L; Stephens J; Farrar WB; Agnese DM
    Ann Surg Oncol; 2009 Oct; 16(10):2691-6. PubMed ID: 19506956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psychosocial factors associated with the uptake of contralateral prophylactic mastectomy among BRCA1/2 mutation noncarriers with newly diagnosed breast cancer.
    Hamilton JG; Genoff MC; Salerno M; Amoroso K; Boyar SR; Sheehan M; Fleischut MH; Siegel B; Arnold AG; Salo-Mullen EE; Hay JL; Offit K; Robson ME
    Breast Cancer Res Treat; 2017 Apr; 162(2):297-306. PubMed ID: 28150129
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Survival outcomes after contralateral prophylactic mastectomy: a decision analysis.
    Portschy PR; Kuntz KM; Tuttle TM
    J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25031308
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Perspectives in the clinical management of BRCA mutations carriers.
    Savarese A; Cognetti F
    J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):31-5. PubMed ID: 12585651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.